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Abstract 
Neuroendocrine Neoplasms (NEN) are a group of heterogeneous malignancies derived from neuroendocrine cell 
compartment, with different roles in both endocrine and nervous system. Most NETs have gastroentero-pancreatic 
(GEP) origin, arising in the foregut, midgut, or hindgut. The 2010 WHO classification divides GEP-NETs into two main 
subgroups, neuroendocrine tumors (NET) and neuroendocrine carcinomas (NEC), according with Ki-67 levels. NET are 
tumors with low (<20 %) Ki-67 value, and NECs, including small cell lung carcinomas and Merkel Cell carcinomas, are 
all NETs with high Ki-67 levels (>20 %–G3). Poorly differentiated neuroendocrine carcinomas (NEC) are usually treated 
with cisplatin-based chemotherapy regimens. Here we present a case of a patient with pancreatic NEC progressing 
after cisplatin and etoposide, treated with temozolomide as palliative, second line treatment. According with the poor 
Performance Status (PS = 2) and to reduce the toxicity of the treatment was chosen an intermittent dosing regimen 
of metronomic temozolomide (75 mg/m2/day—one-week-on/on-week-off ). MGMT resulted methylated. On July 
2014 the patient started the treatment. On August 2014 the patient obtained a significant clinical benefit (PS = 0) and 
the total body CT scan performed on October 2014 showed a RECIST partial response on all the sites of disease. No 
drug-related side effects were reported by the patient. After 18 months of therapy the treatment continues without 
significant toxicity, and with further remission of the metastases. Treatment with metronomic “one-week-on/on-week-
off” Temozolomide can be considered a good treatment option in patients with poor performance status, affected by 
pNEC with MGMT methylation.
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Background
Neuroendocrine tumors (NETs) are a heterogeneous 
group of malignancies derived from neuroendocrine cell 
compartment [1, 2], with roles in both endocrine and 
nervous system. The treatment strategy of NET varies 
according with several factors, such as tumor differentia-
tion, stage at diagnosis, and presence or absence of symp-
toms related to hormonal secretion. Surgical resection 
represents the traditional treatment of NETs and it is the 
only curative approach. However, the surgical excision is 
not always possible because most of the patients are met-
astatic at the diagnosis, with regional or distant metasta-
ses observed in about 50 % of patients. 65 % of pancreatic 
NETs (pNET) are diagnosed when the disease is already 
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control tumor growth in patients with advanced (unre-
sectable or metastatic) NET. In patients with advanced 
NETs, the treatment goal is to control hormone-related 
symptoms (if the tumor is functional), tumor growth, 
and prolong overall survival of the patients. Biotherapy 
with somatostatin analogs (SSAs) remains the mainstay of 
symptomatic therapy [5, 6]. More recently, the PROMID 
study has shown that octreotide LAR (long-acting release) 
increased time to tumor progression (TTP), as compared 
with placebo, from 6 to 14.3  months in treatment-naive 
patients with advanced NET of midgut origin [7]. These 
findings have been confirmed and extended by the recent 
CLARINET trial with lanreotide [8], published in 2014. 
This trial showed a significantly prolonged progression-
free survival (PFS) in patients with metastatic grade 1 or 
2 (Ki-67 <10 %) enteropancreatic neuroendocrine tumors. 
Somatostatin analogues can inhibit the tumor growth and 
stabilize disease irrespective of the hormonal activity of 
the tumor. Cytoreductive surgery and regional ablation 
are used with palliative intent in metastatic disease. Local 
cytoreductive/ablative therapies include hepatic (chemo) 
embolization, percutaneous ethanol injection, cryo-
therapy, radiofrequency ablation, and selective internal 
radiation with Yttrium-90 labeled microspheres [9]. Their 
impact on survival has to be proven in larger, controlled 
trials. Peptide radionuclide receptor therapy (PRRT) 
seems to be a promising treatment option but there are 
not data available from randomized controlled trials and 
this therapy is not available worldwide [10].
Chemotherapy was, for years, the only therapeutic 
option for the treatment of metastatic pNET, with very 
contradictory results. Considering that Neuroendocrine 
Carcinomas (NECs) have common embryological ori-
gin and similar histologic morphology of small cell lung 
cancer and Merkel Cell carcinomas, the combination of 
cisplatin plus etoposide is usually the favorite treatment 
schedule of poor differentiated neuroendocrine tumors. 
Although this platinum-based combination treatment 
had shown interesting results in terms of response rate 
on undifferentiated NETs [11], there was a minimal 
impact on overall survival, so these results remain con-
troversial. Actually the schedule cisplatin plus etoposide 
is only a virtual standard therapy. The traditional use of 
this scheme derives from old studies, with little statistical 
evidences due to the small number of patients enrolled in 
clinical trials. Therefore it is uncertain that cisplatin and 
etoposide can be considered the gold standard for the 
treatment of these tumors. Furthermore other drugs, as 
gemcitabine, oxaliplatin or temozolomide can be evalu-
ated in the treatment of NEC.
Temozolomide (TMZ) is an imidazotetrazine deriva-
tive of the alkylating agent dacarbazine, which shows 
good central nervous system distribution. The use of 
TMZ is particularly indicated in the treatments of brain 
tumors, primary central nervous system lymphoma, neu-
roendocrine and pituitary tumors. TMZ was approved by 
the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) in 1999 for the treatment of 
multiform glioblastoma and anaplastic astrocytoma in 
case of recurrence or progression after standard therapy 
and in 2005 for newly diagnosed multiform glioblastoma 
in combination with radiotherapy and then as mainte-
nance treatment.
The activity of TMZ in patients with metastatic neu-
roendocrine tumors has been evaluated in several trials 
[11, 12] which showed an interesting activity in terms of 
ORR, ranging from 25 to 70 %. [13–21]. TMZ showed a 
good activity in patients with NETs both in monother-
apy both in association with other anti-cancer drugs as 
capecitabine, bevacizumab or thalidomide.
The association of TMZ plus capecitabine showed 
encouraging results. In vitro data indicate that this com-
bination has a synergistic effect, inducing apoptosis in 
neuroendocrine tumor cell lines. A retrospective study of 
17 patients with pNETs treated with TMZ plus capecit-
abine showed 1 complete response (6  %) and 9 partial 
responses (54 %), with a median duration of response of 
284 days. All of the patients progressed during first-line 
treatment with escalating doses of sandostatin LAR, and 
11 patients during multiagent chemotherapy (range 1–5 
regimens) [22].
Moreover the association of TMZ plus capecitabine 
resulted particularly active in patients both with well, 
both with poor differentiated pancreatic neuroendocrine 
tumours.
In a trial reported by Strosberg et  al. in 2011 [23], 30 
patients with progressive metastatic pNETs, all chemo-
therapy-naïve, were treated with capecitabine (750  mg/
m2 b.i.d., d. 1–14) plus temozolomide (200  mg/m2/day, 
d. 10–14) every 28 days. 70 % of the patients achieved a 
RECIST objective response, median progression-free 
survival was 18  months, and the 2  years survival rate 
resulted 92 %. Four patients (12 %) experienced grade 3 
or 4 adverse events (Table 1).
Therefore, these combination have a promising activ-
ity that should be evaluated in further studies with larger 
cohorts of patients to confirm the efficacy of these and to 
find the optimal schedule of association with other drugs. 
An interesting clinical trial from ECOG (ACRIN Cancer 
Research Group-E 2211) on these issues is ongoing.
Traditionally, neuroendocrine tumors have been clas-
sified by their anatomic site of origin. NETs can arise 
in many different areas of the body, and are most often 
located in the intestine, pancreas or the lungs. The vari-
ous kinds of cells that can give rise to NETs are present 
in  endocrine glands and are also diffusely distributed 
Page 3 of 12De Divitiis et al. J Transl Med  (2016) 14:113 
throughout the body. But all the NETs have a common 
embryologic origin from the neural crest. So between the 
neuroendocrine cancers are included different tumors as 
small cell lung cancer and Merkel cell carcinoma.
In the landscape of anti- tumor therapy, recently the 
immunotherapy has found a new field of application. 
Indeed, It has been proven that the tumors may adopt 
normal physiologic checkpoints for immunomodula-
tion leading to an imbalance between tumor growth and 
host surveillance. Antibodies targeting the PD-1/PD-L1 
checkpoint have shown dynamic and durable tumor 
regressions, suggesting a rebalancing of the host–tumor 
interaction. Nivolumab and Pembrolizumab are the anti-
PD-1 antibodies that are currently the furthest in clinical 
development, and anti-PD-L1 agents under investiga-
tion include MPDL3280A, MEDI4736, and BMS-936559. 
These agents have been used to treat advanced mela-
noma, non-small cell lung cancer, renal cell carcinoma, 
bladder cancer and Hodgkin lymphoma, amongst other 
tumor types.
In the treatment of small cell lung cancer (SCLC), an 
aggressive neoplasm thought to be arising from lung neu-
roendocrine cells, several trial are ongoing to investigate 
PD-L1 and PD-1 expression patterns and the role of anti-
tumour immunotherapy such as blockade of co-inhibi-
tory immune pathways PD-1/PD-L1.
Ott and others [24] have observed, in the ongoing 
trial Keynote-028, that, in the treatment of patients with 
PD-L1 + SCLC who have progressed on prior platinum-
based therapy, Pembrolizumab is generally well tolerated 
and, therefore, has promising antitumor activity. In fact, 
it has been demonstrated that out of the 135 patients 
with SCLC screened, 37 (27  %) had PD-L1  +  tumors 
and of 16 treated with pembrolizumab (Pembrolizumab 
10  mg/kg every 2 weeks for up to 2 years or until con-
firmed progression or unacceptable toxicity), 4/16 (25 %) 
evaluable patients had a partial response.
Pembrolizumab has promising antitumor activ-
ity also in the treatment of Merkel cell carcinoma 
(MCC). MMC is an aggressive neuroendocrine car-
cinoma of the skin, which can be distinguished from 
other malignancies by its expression of cytokeratin 20. 
Meantime, it is already known that, in cancer immu-
notherapy, dendritic cells (DCs) play a fundamental 
role in the dialog between innate and adaptive immune 
response, but several immunosuppressive mechanisms 
remain to be overcome. For example, a high num-
ber of CD4  +  CD25  ++  Foxp3+  regulatory T-cells 
(Foxp3  +  Tregs) have been observed in the peripheral 
blood and tumor microenvironment of cancer patients. 
On the basis of this, Ridolfi and others [12] conducted a 
study on DC-based vaccination in advanced melanoma, 
adding low-dose temozolomide to obtain lymphodeple-
tion. They founded that the combined immunological 
therapy, at least as far as the DCR subgroup is concerned, 
effectively reduced the number of Foxp3  +  Treg cells, 
which exerted a blunting effect on the growth stimulat-
ing effect of IL-2. However, this regimen, with its current 
modality, would not seem to be capable of improving 
clinical outcome.
Here we present a case of a patient with poor Perfor-
mance Status (PS), affected by a pancreatic neuroendo-
crine tumor, progressing after a first line of therapy with 
cisplatin plus etoposide, achieving a clinical and radio-
logical response with metronomic temozolomide “one-
week-on/on-week-off regimen”, with continuing tumor 
shrinkage at 18 months from the beginning of the treat-
ment. The intermittent dosing was chosen to reduce the 
frequency and severity of hematologic toxicity of TMZ 
as compared with more extended dosing schedules such 
as the 21/28-day or extended daily schedules, and for the 
poor Performance Status (PS =  2) of the patient at the 
beginning of the treatment.
According to the present knowledge it wouldn’t be rash 
to claim that the treatment with TMZ can develop mech-




On September 2012 a 57-year-old female patient, due to 
repeated episodes of heartburn and dyspepsia, under-
went endoscopy examination of the stomach that diag-
nosed the presence of gastritis with duodenal ulcer and 
Helicobacter Pilory (HP) infection. Blood tests showed an 
increase of AST, ALT and amylase. She also practiced an 
abdomen ultrasound that resulted negative for metastatic 
lesions. Therefore, was prescribed antibiotic therapy for 
Table 1 Main trial testing temozolomide in neuro-endocrine carcinomas (ORR;PFS;OS)
References Regimens ORR (%) PFS (ms) OS (ms)
Moertel [11] Etoposide130 mg/mq iv ds 1–3 plus Cisplatin 45 mg/m2 iv ds 2–3 67 8 19
Ekeblad [14] Temozolomide 200 mg/m2 os ds 1–5, q28 14 7 16
Welin [18] Temozolomide 150–200 mg/m2 os ds 1–5, q28 ± Capecitabine 1000 mg os bid or 750 mg bid, ds 1–14 33 6 22
Strosberg [17] Capecitabine 750 mg/m2 os bid, ds 1–14 plus Temozolomide 200 mg/m2 os ds 10–14, q28 70 18 n.d.
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HP eradication and introduced a regimen with protonic 
pump inhibitor (PPI). On July 2013, due to the worsen-
ing of nausea and vomiting was performed a total body 
CT-scan, which evidenced the presence of an advanced 
neoplasia of the pancreatic head with lymph nodal, liver, 
spleen and lung metastases. Hematology showed high 
levels of chromogranin A up to 371.0 U/L (n.v. 2.0 to 
18.0) and 5HIAA up to 18 (<8). Then a liver biopsy under 
ultrasound guidance was performed. The histological 
examination diagnosed the presence of a poorly differen-
tiated, endocrine-small cell carcinoma, (NEC) (CD56+; 
chromogranin +, synaptophysin +, CK7−; Ki67 >20 %) 
(Fig.  1) and also detected peritumoral lymphocytes and 
leukocytes infiltrating tumor micro environment (Fig. 2).
An OctreoScan performed on July 18 2013 showed the 
presence of hypermetabolic indicator receptor on the 
right subclavian region, retrotracheal, subcarinal, epi-
mesogastric region (pancreas and lymphnodes), on mul-
tiple areas of the liver and on some skeletal sites (skull, 
dorsal vertebra and pelvis).
A PET-FDG practiced on July 20, 2013 showed patho-
logical uptake at the pancreas (SUV max 4), at some liver 
lesions (SUV max 3) and at multiple skeletal localiza-
tions, in particular on the right humerus, on D4 and on 
the left acetabulum.
On July 27 2013, the patient arrived at Our Insti-
tute presenting highly symptomatic disease (vomiting 
G2, diarrhea G2, heartburn); laboratory tests showed 
elevation of AST (=93), ALT (=156) and GGT (=321). 
Therefore on July 20 2013 was prescribed treatment with 
octreotide LAR 30 every 4  weeks (q28) and on July 31 
2013 the patient started a first-line chemotherapy with 
the combination cisplatin plus etoposide.
On March 2014 after six cycles of chemotherapy, the 
patient underwent total body CT-scan that showed 
radiological stable disease, with clinical response for the 
resolution of the disease-related symptoms and normali-
zation of liver function tests. The patient continued the 
treatment with octreotide LAR 30 q28 but on June 2014, 
after three months of therapy there was a clinical pro-
gression of disease with worsening of performance status 
(ECOG PS = 2).
If the first line of chemotherapy in neuroendocrine car-
cinomas with cisplatin and etoposide is not a real stand-
ard therapy, a second line therapy for NEC progressing 
patients does not really exist. Thus, considering the poor 
clinical status, we prescribed a treatment with temozo-
lomide 75  mg/m2 “one week on/one week off”. On July 
2014 the patient started the treatment. Metronomic 
temozolomide was well tolerated and no drug-related 
side effects were reported by the patient. The detection 
of MGMT methylation, by MSP and MethyLight qMSP, 
resulted positive (Fig. 3).
On August 2014, the patient had a significant clinical 
benefit with improvement of performance status (ECOG 
PS: 0). The total body CT-scan performed on October 
2014 evidenced a RECIST partial response (Figs. 4, 5, 6) 
with reduction in number and volume of liver and spleen 
Fig. 1 Histological examination with immunohistochemistry and hematoxylin-eosin staining (e/e). a CD 56 20 × magnification; b e/e 20 × magni-
fication; c chromogranin 20 × magnification; d Synaptophysin 20 × magnification; e Ki-67 40 × magnification
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metastases, reduction of hepatomegaly and splenomeg-
aly, reduction of periesofageal, retrocrural and lomboaor-
tic lymphnodal metastases, reduction of lung metastases, 
disappearance of ascites, significantly reduction of the 
lesion of the pancreatic head.
The patient continued the treatment and the total body 
CT-scan performed on January 2015 showed once again 
the persistence of the framework of further instrumental 
disease response, on lung, liver, and multiple lymphnodal 
metastases. Then, given the response both clinical and 
radiological and considering the improvement in quality 
of life and Performance Status achieved by the patient, 
we continued the treatment with temozolomide at the 
same dosage and regimen. In April 2015, the patient, sta-
ble for clinical conditions (PS = 0), with very good qual-
ity of life, performed a new total body CT-scan (Figs. 4, 5, 
6) which showed an unexpected, further partial response. 
Treatment with TMZ is still ongoing.
Discussion
Despite new promising therapeutic strategies in the set-
ting of G1 – G2 pNET, recurrent or metastatic pancre-
atic Neuroendocrine Carcinoma (pNEC) continues to be 
an incurable disease with poor prognosis and there is no 
standard option for second line chemotherapy. Ongoing 
clinical trials are testing the efficacy of immune modu-
lating antibodies against the PD-1/PDL-1 pathway (i.e. 
Avelumab in Merkel Cell Carcinoma) in pre-treated, 
progressing neuroendocrine tumors (NCT01772004, 
NCT01375842).
Few prospective studies that investigate a second line 
chemotherapy in neuroendocrine tumors are available.
Fig. 2 Peritumoral lymphocytes and leucocytes infiltrating tumor microenviroment. Tumor-infiltrating CD8 + T cells (circles) have been detected in 
the pNEC tumor biopsy of the patient. These cells infiltrating tumor micro environment are frequently associated with favorable clinical outcome in 
a remarkably large spectrum of cancers as MCC and pNEC
Fig. 3 Detection of MGMT methylation by MSP and MethyLight 
qMSP. Isolated DNA from tumor specimen is treated with sodium 
bisulfite, which changes unmethylated cytosine (C) into uracil (U), but 
not methylated cytosine (mC), which remains unchanged. The modi-
fied DNA is used as a template for MSP or MethyLight qMSP. (MSP/
agarose gel electrophoresis) When MGMT in neuroendocrine tumor is 
methylated (DNA M), the band is high, while the unmethylated band 
(DNA U) is low. The gel shows the presence of methylation band in 
BT1, brain tumor a with strong methylated, DNA M, used as positive 
control, and unmethylation band in BT2, brain tumor a with strong 
unmethylated, DNA U, used as negative control
Page 6 of 12De Divitiis et al. J Transl Med  (2016) 14:113 
Page 7 of 12De Divitiis et al. J Transl Med  (2016) 14:113 
In 2011 Welin et  al. [25] showed that Temozolomide 
may be an active, well tolerated, second-line chemo-
therapy regimen for NEC patients (mainly gastrointesti-
nal) who have progressed after first-line chemotherapy. It 
seems to be effective also in lung carcinoid.
Early clinical studies [26, 27] investigating shortened 
and extended dosing schedules suggested that continu-
ous daily administration of temozolomide resulted more 
effective than a single dose. More frequent administra-
tion (e.g., twice a daily) yielded higher levels of O6-meth-
ylguanine DNA adducts, suggesting that the capacity 
of tumor cells to repair these adducts can be saturated. 
Unfortunately, hematologic toxicity was dose limiting of 
some schedules.
In Glioma, it has been suggested that intermittent dos-
ing (one week on/one week off treatment) may reduce the 
frequency and severity of hematologic toxicity compared 
with more extended dosing schedules such as the 21/28-
day or extended daily schedules [28].
Several studies [28] have shown that prolonged expo-
sure to temozolomide can deplete MGMT activity in 
blood cells, a process that could potentially increase the 
antitumor activity of the drug. To date, however, there 
are limited data demonstrating the depletion of MGMT 
activity in tumor tissue exposed to temozolomide. Wolf-
gang [28] et al. studied in patients with glioma the effects 
of the treatment with either an alternating weekly sched-
ule (7 days on/7 days off) or for 21 consecutive days every 
28-day cycle (21/28-day schedule) on MGMT enzyme 
activity assayed in peripheral blood mononuclear cells 
(PBMCs). The results showed a time- and dose-depend-
ent decrease in MGMT activity with both regimens.
A variety of dosing schedules that increase the duration 
of exposure and the cumulative dose of temozolomide 
are currently being investigated for the treatment of gli-
oma, with the goal of improving antitumor activity and 
overcoming resistance [29–32]. These alternative dosing 
regimens have been shown to deplete MGMT activity in 
peripheral blood mononuclear cells, but the regimen that 
provides the best balance between enhanced antitumor 
activity and acceptable hematologic toxicity has yet to be 
determined.
According with these considerations, we decided to use 
the regimen “Seven-Days-On/Seven-Days-Off Regimen” 
because it appears to reduce the frequency and severity 
of hematologic toxicity as compared with more extended 
dosing schedules such as the 21/28-day or extended daily 
schedules.
In our case, we treated a metastatic pNEC patient, pro-
gressing after a first line platinum-based chemotherapy, 
with metronomic regimen (75 mg/m2/day) of temozolo-
mide “one week on/one week off”.
After 1  month of treatment, a clinical response, with 
regression of disease-related symptoms and performance 
status improvement from ECOG PS 2 to 0 was obtained. 
After 3 months of therapy a RECIST partial response was 
observed. The treatment was well tolerated without drug-
related side effects. After 18 months of therapy the par-
tial response goes on.
Though on the tumor samples of patient the detection 
test of MGMT methylation was positive, we think that 
this result cannot be due only to the action of the alkylat-
ing drug, but needs immunological implications of the 
chemotherapy.
Conventional anticancer chemotherapy is generally 
thought to act through selective killing of tumor cells or 
by irreversibly arresting their growth. Cytotoxic drugs act 
in different phases of cell cycle interfering with DNA syn-
thesis, or inducing a damage on DNA, leading to tumor 
cell death. Always more evidences indicate that several 
chemotherapeutic agents are more active against tumors 
implanted in immunocompetent hosts as compared with 
tumors in immunodeficient hosts. This clearly indicates 
the existence of a correlation between the activity of 
chemotherapeutic agents and the hosts’ immune system 
[28].
(See figure on previous page.) 
Fig. 4 Hepatomegaly reduction. CT portal-phase contrast-enhanced images: Coronal plane reconstruction and Axial Maximum Intensity Projection 
(MIP) reconstruction at time 0 (a) and at 4 (b), 7 (c), 10 month (d) follow up examinations. Progressive reduction of longitudinal diameter of the liver 
measured in the mid-clavicular line was observed at follow up study. Progressive reduction of lower margin extension below costal arch was also 
detected. Caudal displacement of right kidney at time 0 (white arrow) gradually disappears at successive studies. Axial MIP images show progres-
sive reduction of the displacement effect on the portal bifurcation due to decrease of metastatic parenchymal lesions: space between left and right 
portal trunk (angle) gradually decrease over time. Note the increased caliber of portal trunks and progressive reduction of the swelling of liver profile 
(arrowhead) related with hepatomegaly, with increased thickness of perivisceral fat
(See figure on next page.) 
Fig. 5 CT portal-phase contrast-enhanced images of two different planes at time 0 (a) and at 4 (b), 7 (c), 10 month (d) follow up examinations. 
Conspicuous volume reduction of paraesophageal and paracardial lymph nodes was observed over time. Increased caliber of portal trunks was 
detected, due to parenchymal architecture changes, reduced mass effect and mild portal hypertension. Note progressive dislocation of left portal 
trunk asterisk from left to right side due to reduction of hepatomegaly. Also note volume decrease of liver and spleen lesions with gradually remission 
of parenchymal architecture
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Fig. 6 Changes of lesions over time in pancreatic head region, lung, liver and spleen at time 0 (a) and at 4 (b), 7 (c), 10 month (d) follow up exami-
nations. Pancreas: enlargement of pancreatic head region was observed at time 0, with strongly inhomogeneous density, indistinct pancreatic 
margins and surrounding retroperitoneal fat stranding; some peripancreatic lymph nodes enlarged were detected. Following CT examinations 
show gradually decrease of pancreatic swelling with better definition of parenchymal lesions, going towards progressive regression e colliquation. 
Note progressive appearance of right kidney’s upper pole asterisk, according to reduction of displacement effect by liver. Furthermore, note the 
displacement of superior mesenteric artery (black arrow) to right side due to reduction of pancreatic swelling. Lung: progressive volume reduction 
of metastatic lesions (white arrow) in anterior basal segment of right lower pulmonary lobe. Liver: one of the major lesions of the liver at the IV seg-
ment (arrowhead) underwent progressive volume reducing ad enhancement pattern. Spleen: volume reduction of multiple metastatic lesions
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Pilot clinical trials with cancer vaccines gave clear evi-
dence of the positive impact of chemotherapy on anti-
tumor immune responses. Gene expression analysis of 
peripheral blood mononuclear cells (PBMCs) from mela-
noma patients treated with dacarbazine and a peptide-
based vaccine revealed, by one day after chemotherapy, 
increased expression of immunoregulatory factors that 
can account for the enhancement of tumor antigen-spe-
cific CD8 T cell responses observed in those patients, as 
compared with patients treated with vaccine alone [33].
Together with these effects were resulted a widening 
of the antigenic repertoire and an expansion of antigen-
specific T-cell tumor reactivity [34].
Moreover cancer often results in an imbalance of Th1/
Th2 immunity, which can be restored by some antineo-
plastic drugs. Besides the active stimulation of effector 
cells, immune-potentiation by cytotoxic chemotherapy 
can also be achieved through the inhibition of tumor-
induced immune suppression.
Several subsets of immunoregulatory cells have been 
identified so far in cancer patients [35].
CD4-CD25-expressing Tregs and myeloid cells with 
suppressive functions, namely myeloid-derived suppres-
sive cells (MDSCs) and tumor-associated macrophages 
(TAMs), accumulate in the blood and, especially, within 
tumor burden, thus contributing to disease progres-
sion through various mechanisms. Gemcitabine kills 
MDSCs, both in vitro and in vivo [36–38] with no signifi-
cant reduction in other cell subsets. The selective loss of 
MDSCs was accompanied by an increase in the antitu-
mor activity of CD8 T and NK cells.
It has been demonstrated that metronomic temozolo-
mide, reduces the number and the suppressive function 
of circulating Tregs in rats bearing glioma, although it 
did not restrain tumor growth [39].
Under defined circumstances, chemotherapy-induced 
tumor cell death can set the stage for an effective anti-
tumor immune response. In fact some chemotherapeu-
tics, including anthracyclines, oxaliplatin and CTX, are 
unique in their capacity to induce an immunogenic type 
of tumor cell death [40, 41] thereby converting dying 
tumor cells into adjuvanted-endogenous vaccines.
An interesting thing to mention is that, the count of 
lymphocytes (ALC) and monocytes (AML) in blood 
samples of our patient has been evaluated, during these 
months. There has been an initial increase and a subse-
quent stabilization of these values over time (Table  2), 
and this is in line with the above hypothesis.
Chemotherapy agents have a significant impact on 
both tumor and host immune system. Even if no system-
atic analysis has been performed to evaluate differences 
in the immune-based effects of conventional chemother-
apeutic agents depending on cancer histology or stage, it 
is now clear that the existence of tumor–host interplay 
influences the magnitude, quality and efficacy of most 
anticancer strategies. Advances in tumor immunology 
have now explained some key mechanisms that represent 
the basis of therapeutic synergy with other treatments.
In our clinical case, the continuous response after 
18  months of treatment, associated with the clinical 
benefit obtained, indicate a plausible immune activation 
induced by metronomic temozolomide. Moreover this 
case report highlights the efficacy and tolerability of this 
regimen even in a patient with poor performance status 
and in this particular category of neoplasms, opening 
new scenarios of treatment for metastatic pNET.
Therefore, this regimen has a promising activity that 
should be evaluated in further studies to confirm the 
efficacy and safety of temozolomide as second-line treat-
ment of Gastro-entero-Pancreatic Neuroendocrine 
Carcinomas progressing after first-line Platinum-based 
therapy, especially in selected patients, such as those who 
have levels of MGMT methylation. A phase II clinical 
trial using temozolomide as second line of NEC progress-
ing after platinum-based first line chemotherapy, has 
been designed (TENEC trial).
Conclusion
This case report highlights the efficacy and tolerability of 
metronomic temozolomide even in this particular cate-
gory of neoplasms and in this therapeutic setting, open-
ing new scenarios of treatment of metastatic pNET.
Therefore, this regimen has a promising activity that 
should be evaluated in further studies to confirm the 
efficacy and safety of Temozolomide for second-line 
treatment of Gastro-entero-Pancreatic Neuroendocrine 
Carcinomas progressing after first-line Platinum-based 
Table 2 Values of  white blood cells, lymphocytes 
and monocytes
The table shows an increase of the percentage values of lymphocytes (ALC) and 
monocytes (AML) in patient blood sample, and a subsequent stabilization of 
these values over time
WBC white blood cells; ALC absolute limphocyte count; AMC absolute monocyte 
count
Date WBC ALC AML
07/15/2014 5910 1040 (17.7 %) 367 (6.21 %)
8/05/2014 11,500 1070 (9.3 %) 878 (7.63 %)
12/11/2014 6950 1459 (21.0 %) 688 (9.9 %)
02/16/2015 5760 826 (14.3 %) 487 (8.44 %)
04/17/2015 6000 756 (14.6 %) 489 (8.15 %)
06/12/2015 4670 655 (14 %) 453 (9.63 %)
07/28/2015 5170 676 (13.1) 435 (8.41)
11/17/2015 6560 800 (11.4 %) 525 (8.0 %)
01/12/2016 6990 997 (14.3) 603 (8.63 %)
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therapy, especially in selected patients, such as those who 
have levels of MGMT methylation.
Recently, a phase II study TENEC, temozolomide as 
second line of NEC in progression after platinum-based 
first line, at our Institution was started.
Abbreviations
GEP: gastro-entero-pancreatic; SSA: somatostatin analog; TTP: time to pro-
gression; NET: neuroendocrine tumor; PRRT: peptide radionuclide receptor 
therapy; TMZ: temozolomide; ORR: overall response rate; AST: aspartato-trans-
ferasi; ALT: alanina-transferasi; PPI: proton pump inhibitor; 5HIAA: hydrox-
yindoleacetic acid; GGT: gamma glutamyl transferase; NEC: neuroendocrine 
carcinoma; MGMT: methylguanine-DNA methyltransferase; PS: performance 
status; PBMCs: peripheral blood mononuclear cells; CTX: cyclophosphamide.
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Appendix: Methods
DNA extraction and bisulfite treatment. To ensure high 
tumour DNA content, FFPE tissue sections were stained 
with H&E and histologically examined by an expert neu-
ropathologist Sections showing a tumour cell content of 
more than 80  % were directly subjected to DNA extrac-
tion.. Extraction of genomic DNA was performed using 
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) 
and quantified with a NanoDrop ND-1000 (PeqLab, Erlan-
gen, Germany). One micrograms of extracted DNA as 
well as CpGenome Universal Methylated DNA (Chemi-
con International, Temecula, CA) and CpGenome Uni-
versal Unmethylated DNA (Chemicon International) as 
controls were subjected to bisulfite treatment using the 
EpiTect Bisulfite Kit (Qiagen). The bisulfite-treated DNA 
was used for Methylation-specific polymerase chain 
reaction (MSP//PCR). The two primer sets established 
by Esteller et  al. for MSP of MGMT [2] were 5′-TTT 
CGACGTTCGTAGGTTTTCGC-3′ (forward primer) 
and 5′-GCACTCTTCCGAAAACGAAACG-3′ (reverse 
primer) for methylated template detection (M primers, 
product length 81  bp; and 5′-TTTGTGTTTTGATGTT 
TGTAGGTTTTTGT-3′ (forward primer) and 5′-AACTC 
CACACTCTTCCAAAAACAAAACA-3′ (reverse primer) 
for unmethylated template detection (U primers, product 
length 93 bp;. The PCR was performed in a total volume of 
20 µl containing 10 µl HotStarTaq Mix (Qiagen), 1 µl of the 
respective forward and reverse primer (10 mol), 6 µl high 
purity water and 2 µl bisulfite-treated template DNA. The 
PCR programme was 95 °C for 15 min, then 35 cycles of 
95 °C for 50 s, 59 °C for 50 s and 72 °C for 50 s, followed 
by a final step at 72  °C for 10  min. PCR reactions with 
CpGenome Universal Methylated DNA (Chemicon Inter-
national), with CpGenome Universal Unmethylated DNA 
Vial A (Chemicon International), and without any DNA 
(non-template control) were included as controls. PCR 
products were separated on a 2 % agarose gel.
Received: 28 October 2015   Accepted: 10 April 2016
References
 1. Williams ED, Sandler M. The classification of carcinoid tum ours. Lancet. 
1963;1:238–9.
 2. Yao JC, Hassan M, Phan A, et al. One hundred years after“carcinoid”: 
epidemiology of and prognostic factors for neuroendocrine tumors in 
35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.
 3. Gastrointestinal Pathology Study Group of Korean Society of Pathologists, 
Cho MY, Kim JM, et al. Current trends of the incidence and pathological 
diagnosis of gastroenteropancreatic neuroendocrine tumors (GEPNETs)in 
Korea 2000–2009: multicenter study. Cancer Res Treat. 2012;44:157–65.
 4. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the 
colon and rectum. Dis Colon Rectum. 2004;47:163–9.
 5. Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr Opin 
Oncol. 2012;24(1):46–55.
 6. Yao JC, Eisner MP, Leary C, et al. Population-based study of islet cell carci-
noma. Ann Surg Oncol. 2007;14:3492–500.
 7. Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, 
double-blind, prospective, randomized study on the effect of octreotide 
LAR in the control of tumor growth in patients with metastatic neuroen-
docrine midgut tumors: a report from the PROMID study group. JCO. 
2009;27(28):4656–63.
 8. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic entero-
pancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224–33. 
doi:10.1056/NEJMoa1316158.
 9. Toumpanakis, et al. Cytotoxic treatment including embolization/
chemoembolization for neuroendocrine tumours. Best Pract Res Clin 
Endocrinol Metab. 2007;21(1):131–44.
 10. Nisa, et al. Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 
expressing tumors: a selected review. Ann Nucl Med. 2011;25(2):75–85. 
doi:10.1007/s12149-010-0444-0 (Epub 2010 Nov 25).
 11. Moertel CG, Kvols LK, O’Connell MJ, et al. Treatment of neuro-endocrine 
carcinomas with combined etoposide and cisplatin. Evidence of major 
therapeutic activity in the anaplastic variants of these neoplasms. Abstr 
US Endocr Soc. 1991;68:227–32.
Page 12 of 12De Divitiis et al. J Transl Med  (2016) 14:113 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 12. Ridolfi L, Petrini M, Granato AM, et al. Low-dose temozolomide before 
dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ 
regulatory T-cells in advanced melanoma patients. J Transl Med. 
2013;11:135. doi:10.1186/1479-5876-11-135.
 13. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. 
Phase II study of temozolomide and thalidomide in patients with meta-
static neuroendocrine tumors. J Clin Oncol. 2006;24:401–6.
 14. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. 
Temozolomide as monotherapy is effective in treatment of advanced 
malignant neuroendocrine tumors. Clin Cancer Res. 2007;15:2986–91.
 15. Kulke M, Blaszkowsky LS, Zhu AX, et al. Phase I/II study of everolimus 
(RAD001) in combination with temozolomide (TMZ) in patients (pts) with 
advanced pancreatic neuroendocrine tumors (NET). 2010 ASCO Gastroin-
testinal Cancers Symposium, January 22-24, 2010 (Abstract).
 16. Koumarianou A, Antoniou S, Kanakis G, Economopoulos N, Rontogi-
anni D, Ntavatzikos A, et al. Combination treatment with metronomic 
temozolomide, bevacizumab and long-acting octreotide for malignant 
neuroendocrine tumours. Endocr Relat Cancer. 2012;19:L1–4.
 17. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line 
chemotherapy with capecitabine and temozolomide in patients with 
metastatic pancreatic endocrine carcinomas. Abstr US Endocr Soc. 
2011;117:268–75.
 18. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical 
effect of temozolomide-based chemotherapy in poorly differentiated 
endocrine carcinoma after progression on first-line chemotherapy. Abstr 
US Endocr Soc. 2011. doi:10.1002/cncr.26124.
 19. Gounaris I, Rahamim J, Shivasankar S, Earl S, Lyons B, Yiannakis D. Marked 
response to a cisplatin/docetaxel/temozolomide combination in a heav-
ily pretreated patient with metastatic large cell neuroendocrine lung 
carcinoma. Anticancer Drugs. 2007;18:1227–30.
 20. Bravo EL, Kalmadi SR, Gill I. Clinical utility of temozolomide in the treat-
ment of malignant paraganglioma: a preliminary report. Horm Metab 
Res. 2009;41:703–6.
 21. Lindholm DP, Eriksson B, Granberg D. Response to temozolomide and 
bevacizumab in a patient with poorly differentiated neuroendocrine 
carcinoma. Med Oncol. 2012;29:301–3.
 22. Isacof WH, Moss RA, Pecora AL, Fine L. Temozolomide/capcitabine 
therapy for metastatic neuroendocrine tumors of the pancreas: a retro-
spective review. J Clin Oncol. 2006;24(20 Suppl):Abstr 14023.
 23. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols 
L. First-line chemotherapy with capecitabine and temozolomide in 
patients with metastatic pancreatic endocrine carcinomas. Cancer. 
2011;117(2):268–75.
 24. Ott PA, Maria Elez-Fernandez ME, Hiret S, Kim DW, Moss RA, Winser T, 
et al. Pembrolizumab (MK-3475) in patients (pts) with extensive-stage 
small cell lung cancer (SCLC): Preliminary safety and efficacy results from 
KEYNOTE-028. J Clin Oncol. 2015;33:abstr 7502.
 25. Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical 
effect of temozolomide-based chemotherapy in poorly differentiated 
endocrine carcinoma after progression on first-line chemotherapy. Abstr 
US Endocr Soc. 2011. doi:10.1002/cncr.26124.
 26. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of 
temozolomide(CCRG 81045: M&B 39831: NSC 362856). Br J Cancer. 
1992;65:287–91.
 27. Newlands ES, Stevens MFG, Wedge SR, Wheelhouse RT, Brock C. Temozo-
lomide: a review of its discovery, chemical properties, preclinical develop-
ment and clinical trials. Cancer Treat Rev. 1997;23:35–61.
 28. Wolfgang Wick, Michael Platten, and Michael Weller, New (alternative) 
temozolomide regimens for the treatment of glioma, Neuro-Oncology, 
2009.
 29. Caroli M, Locatelli M, Campanella R, et al. Temozolomide in glioblastoma: 
results of administration at first relapse and in newly diagnosed cases. 
Is still proposable an alternative schedule to concomitant protocol? J 
Neurooncol. 2007;84:71–7.
 30. Chinot OL, Barrie M, Fuentes S, et al. Correlation between O6-methylgua-
nine- DNA methyltransferase and survival in inoperable newly diagnosed 
glioblastoma patients treated with neoadjuvant temozolomide. J Clin 
Oncol. 2007;25:1470–5.
 31. Combs SE, Gutwein S, Schulz-Ertner D, et al. Temozolomide combined 
with irradiation as postoperative treatment of primary glioblastoma 
multiforme. Phase I/II study. Strahlenther Onkol. 2005;181:372–7.
 32. Combs SE, Schulz-Ertner D, Welzel T, Bischof M, Debus J. Re-irradiation 
using high precision radiotherapy and concomitant temozolomide in 
patients with recurrent glioma: re-challenge with radio-chemotherapy 
[abstract 12517]. J Clin Oncol. 2007;25(suppl):606s.
 33. Tai-Gyu Kim,Chang-Hyun Kim,Jung-Sun Park,Sung-Dong Park,Chung 
Kwon Kim, Dong-Sup Chung,and Yong-Kil Hong. Immunological Factors 
Relating to the Antitumor Effect of Temozolomide Chemoimmunother-
apy in a Murine Glioma Model. Clin Vaccine Immunol. 2010;17:143–53.
 34. Nistico P, Capone I, Palermo B, Del Bello D, Ferraresi V, Moschella F, et al. 
Chemotherapy enhances vaccine-induced antitumor immunity in mela-
noma patients. Int J Cancer. 2009;124:130–9.
 35. Palermo B, Del Bello D, Sottini A, Serana F, Ghidini C, Gualtieri N, et al. Dac-
arbazine treatment before peptide vaccination enlarges T-cell repertoire 
diversity of melan-a- specific, tumor-reactive CTL in melanoma patients. 
Cancer Res. 2010;70:7084–92.
 36. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: 
tumor escape from the immune system. Cancer Immunol Immunother. 
2011;60:1161–71.
 37. Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, et al. 
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppres-
sor cells resulting in enhanced T-cell-dependent antitumor immunity. 
Cancer Res. 2010;70:3052–61.
 38. Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez AC, Benninger K, Khan M, 
Kuppusamy P, et al. Myeloid-derived suppressor cell inhibition of the IFN 
response in tumor-bearing mice. Cancer Res. 2011;71:5101–10.
 39. Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-
dose metronomic temozolomide regimen in a rat glioma model. Cancer 
Immunol Immunother. 2009;58:1627–34.
 40. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. 
Cyclophosphamide synergizes with type I interferons through systemic 
dendritic cell reactivation and induction of immunogenic tumor apopto-
sis. Cancer Res. 2011;71:768–78.
 41. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostim-
ulation by anticancer drugs. Nat Rev Drug Discov. 2012;11:215–33.
